



Corrigendum

Corrigendum to “Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway” [Int. Immunopharmacol. 36 (2016) 132–141]




Hong Yao^{a,1}, Changsheng Hu^{b,1}, Lianhong Yin^a, Xufeng Tao^a, Lina Xu^a, Yan Qi^a, Xu Han^a, Youwei Xu^a, Yanyan Zhao^a, Changyuan Wang^a, Jinyong Peng^{a,*}

^a College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

^b Huanggang Polytechnic College, No. 109 Taoyuan St., Nanhu Educational District, Huanggang City 438002, Hubei Province, China

The authors regret that there was an error in Fig. 5A. During the course of revision, the figure of the expression of MyD88 in AML-12 cells based on immunofluorescence assay was accidentally wrongly used. We have provided correct Fig. 5A, which showed no influence to the results. The authors would like to apologise for any inconvenience caused.



Corrected Fig. 5A. Effects of dioscin on TLR4 and MyD88 levels based on immunofluorescence assay in AML-12 cells ($\times 400$ original magnification).

DOI of original article: <https://doi.org/10.1016/j.intimp.2016.04.023>

* Corresponding author.

E-mail address: jinyongpeng2008@126.com (J. Peng).

¹ These authors contributed the same work to this paper and they are the co-first authors.

<https://doi.org/10.1016/j.intimp.2019.105786>

Available online 08 August 2019

1567-5769/ © 2019 Elsevier B.V. All rights reserved.